KindredBio Partners with Vaxart for COVID-19 Oral Vaccine

KindredBio has partnered with Vaxart to mass produce Vaxart’s oral capsule vaccine candidate for COVID-19, which would have an advantage over injected vaccines because of its simpler delivery method.

The agreement builds on an existing partnership between the two San Francisco-based companies. KindredBio subsidiary Centaur Biopharmaceutical Services will manufacture the vaccines at facilities in California and Kansas.

The new deal also includes other vaccines Vaxart is developing for norovirus, seasonal influenza, respiratory syncytial virus and human papillomavirus.